Danaher Corporation (DHR)은 1분기 조정 EPS 호실적 발표

Danaher Corporation (NYSE:DHR) is one of

10 Best Slow Growth Stocks to Buy According to Analysts.

On April 21, 2026, Danaher Corporation (NYSE:DHR) reported Q1 adjusted EPS of $2.06, above the $1.94 consensus, with revenue of $6B in line with expectations. Rainer Blair said the company “executed well in the first quarter,” citing nearly 10% adjusted EPS growth, continued recovery in Bioprocessing, and better-than-expected performance in Life Sciences, which helped offset a lighter respiratory season at Cepheid. Rainer Blair also pointed to the planned acquisition of Masimo Corporation, noting opportunities to improve performance through scale and operating capabilities.

The company raised its FY26 adjusted EPS outlook to $8.35–$8.55 from $8.35–$8.50, compared with a $8.40 consensus, and reiterated expectations for non-GAAP core revenue growth of 3% to 6% year-over-year. Danaher also highlighted its balance sheet and free cash flow generation as supporting further capital deployment.

Following the results, Jefferies analyst Tycho Peterson raised the price target on Danaher Corporation (NYSE:DHR) to $245 from $240 and maintained a Buy rating after what was described as a “solid” Q1, noting easing headwinds, emerging growth signals, and valuation that is “not demanding.”

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services globally.

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **

Disclosure: None. Follow Insider Monkey on Google News**.